Market Cap (In USD)
2.98 Million
Revenue (In USD)
-
Net Income (In USD)
-9.34 Million
Avg. Volume
1.12 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.432-20.16
- PE
- -0.01
- EPS
- -147.36
- Beta Value
- 0.555
- ISIN
- IL0011651580
- CUSIP
- M77798102
- CIK
- 1801834
- Shares
- 1706230.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Ilan Hadar M.B.A.
- Employee Count
- -
- Website
- https://www.painreform.com
- Ipo Date
- 2020-09-01
- Details
- PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
More Stocks
-
GANDHAR
-
1717
-
3639
-
GFGUGetFugu, Inc.
GFGU
-
HESTERBIOHester Biosciences Limited
HESTERBIO
-
CORCencora
COR
-
SNIPFSnipp Interactive Inc.
SNIPF
-
1771